Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries is a research-based international pharmaceutical company that develops high-quality, proprietary and off-patent pharmaceuticals for markets in the US, Canada, Israel and other countries. The company emphasizes research and development as key to its growth strategy.

Taro Pharmaceutical Industries

Wellness and Fitness Services

Alchemee (formerly The Proactiv Company)

Pharmaceutical Manufacturing

TARO PHARMACEUTICALS CANADA

Taro Pharmaceuticals | 39,759 followers on LinkedIn. Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Avi Avramoff, R.Ph, Ph.D

Taro Pharmaceuticals

The Taro Generics team kicked off the summer with an outing to a Rockland Boulders game. The event was a fantastic opportunity for everyone to bond outside of work and strengthen our camaraderie. #TeamTaro

For over 50 years Taro Pharmaceuticals has manufactured Warfarin, a medication clinically shown to reduce the risk of death after myocardial infarction. Taro remains committed to manufacturing this and other lifesaving medications. Visit https://lnkd.in/d44_y6p5 for full prescribing information and medication guide.

Taro Pharmaceuticals is attending the National Association of Chain Drug Stores (NACDS) Annual Meeting this weekend. Stop by table 546 to meet with CEO Uday B. , VP of Generics Anthony Dolan , and VP of OTC Nivaran Kapur . We look forward to seeing you! #NACDSANNUAL #TeamTaro

On International Women’s Day, we would like to take this opportunity to reflect on the achievements and contributions of the women of Taro. Women make up 45% of our global workforce and hold nearly 50% of management level positions within the company. These numbers support Taro's aspiration to be an inclusive workplace where everyone feels valued, respected and has the opportunity to thrive. When we look at the data at a country level, the trend is similar: · In the United States, our workforce is nearly 50% women, and women hold 45% of management level positions. · In Israel, while women make up 44% of the workforce, they hold 57% of management level positions. · In Canada, 43% of our workforce are women, and they hold 46% of our management level positions. · In Japan, 61% of our workforce are women, and they hold 60% of management level positions. Additionally, women are strongly represented across our organization, even in fields that have been traditionally dominated by men. For example, globally women comprise 61% of our R&D/Regulatory/Clinical team, 66% of our Quality team, and 58% of our Supply Chain team. We are proud of the progress Taro has made in promoting gender equality and the advancement of women, and we will continue to work to ensure that Taro is a workplace where everyone has the opportunity to succeed and feels that they belong. #IWD2024 #InspireInclusion #TeamTaro

March is Blood Clot Awareness Month. Did you know that blood clots can affect anyone, anytime? This month, let's spread awareness and knowledge about the risks, signs, and preventive measures. #BCAM2024 #BCAM #TeamTaro

In recognition of American Heart Month, we were proud to partner with the Congenital Heart Defect Coalition to put together Kits of Hope for young children with heart defects who are awaiting treatment in hospitals across the country. Our Taro team members in Hawthorne, NY, assembled 100 kits that will be sent to the Children’s Hospital of Philadelphia, Children’s Hospital at Montefiore, Cohen Children’s Center, Northwell Health, Icahn School of Medicine at Mount Sinai, Boston’s Children’s Hospital and Columbia Medical Center. Thank you to our Taro volunteers for helping make a difference to these patients and their families! #TeamTaro

Taro Pharmaceuticals will be attending the National Association of Chain Drug Stores (NACDS) Annual Meeting in April. We look forward to seeing you there! #NACDSANNUAL #TeamTaro

Taro was honored to receive the Partnership in Quality Award at last week's GSMS, Incorporated annual STAR Summit. Congratulations to the team for this recognition!

	Mar '14	Mar '15	Mar '16	Mar '17	Mar '18	Mar '19	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
revenue	759.28M -	862.94M 13.65%	950.75M 10.18%	879.39M 7.51%	661.91M 24.73%	669.89M 1.21%	644.77M 3.75%	548.97M 14.86%	561.35M 2.25%	572.95M 2.07%	629.18M 9.81%
cost of revenue	179.28M -	186.36M 3.95%	171.78M 7.82%	208.14M 21.16%	198.41M 4.68%	224.17M 12.99%	245.04M 9.31%	252.31M 2.97%	268.23M 6.31%	304.63M 13.57%	324.20M 6.43%
gross profit	580.01M -	676.59M 16.65%	778.97M 15.13%	671.25M 13.83%	463.51M 30.95%	445.72M 3.84%	399.73M 10.32%	296.66M 25.78%	293.12M 1.19%	268.32M 8.46%	304.98M 13.66%
selling and marketing expenses							36.66M -		56.62M -	113.28M 100.07%
general and administrative expenses							56.76M -		57.06M -	85.09M 49.12%
selling general and administrative expenses	91.73M -	87.64M 4.46%	92.36M 5.39%	85.66M 7.26%	88.20M 2.97%	89.97M 2.01%	93.41M 3.83%	91.36M 2.20%	113.68M 24.43%	198.37M 74.50%	218.94M 10.37%
research and development expenses	55.43M -	65.51M 18.19%	71.16M 8.62%	70.64M 0.73%	70.42M 0.32%	63.24M 10.20%	59.78M 5.47%	60.15M 0.63%	54.54M 9.33%	52.24M 4.21%	64.54M 23.53%
other expenses	1.37M -	2.74M 100%	2.68M 2.12%	11.21M 318.32%	1.89M 83.15%	1.81M 4.18%	3.02M 66.74%	2.89M 4.17%	4.23M 46.13%	2.46M 41.74%	64.54M 2,521.28%
cost and expenses	326.44M -	339.51M 4.00%	335.31M 1.24%	364.44M 8.69%	357.02M 2.04%	377.38M 5.70%	398.23M 5.53%	403.82M 1.40%	436.44M 8.08%	555.24M 27.22%	607.67M 9.44%
operating expenses	147.16M -	153.15M 4.07%	163.53M 6.77%	156.30M 4.42%	158.61M 1.48%	153.21M 3.41%	153.19M 0.01%	151.51M 1.10%	168.22M 11.03%	250.61M 48.98%	283.47M 13.11%
interest expense	1.51M -	928K 38.75%	473K 49.03%	131K 72.30%	304K 132.06%	256K 15.79%	725K 183.20%	1.36M 88%	1.65M 21.28%	-17.69M 1,169.93%
ebitda	444.88M -	493.39M 10.90%	624.19M 26.51%	509.61M 18.36%	355.74M 30.19%	282.13M 20.69%	253.08M 10.29%	728.12M 187.70%	210.28M 71.12%	52.65M 74.96%	52.60M 0.10%
operating income	430.25M -	527.63M 22.63%	614.47M 16.46%	514.95M 16.20%	303.01M 41.16%	296.19M 2.25%	246.53M 16.77%	704.44M 185.74%	184.37M 73.83%	17.71M 90.39%	21.51M 21.42%
depreciation and amortization	16.57M -	15.80M 4.64%	14.85M 6.01%	14.83M 0.13%	16.50M 11.24%	18.60M 12.74%	6.55M 64.80%	23.68M 261.75%	25.91M 9.44%	34.94M 34.83%	31.09M 11.01%
total other income expenses net	5.90M -	48.57M 723.67%	8.78M 81.93%	31.38M 257.60%	-32.46M 203.44%	30.80M 194.88%	51.50M 67.22%	-1.10B 2,227.21%	-106.51M 90.28%	20.50M 119.25%	61.16M 198.36%
income before tax	443.91M -	581.68M 31.04%	636.82M 9.48%	560.80M 11.94%	292.37M 47.87%	356.85M 22.06%	298.04M 16.48%	-391.07M 231.22%	77.86M 119.91%	38.21M 50.92%	82.67M 116.33%
income tax expense	82.73M -	96.06M 16.11%	95.31M 0.78%	103.78M 8.88%	81.95M 21.03%	74.73M 8.81%	53.48M 28.43%	9.67M 81.93%	19.59M 102.67%	12.77M 34.83%	28.80M 125.57%
net income	360.39M -	484.26M 34.37%	540.93M 11.70%	456.36M 15.64%	211.15M 53.73%	281.78M 33.45%	244.24M 13.32%	-400.74M 264.08%	58.27M 114.54%	25.45M 56.33%	53.87M 111.70%
weighted average shs out	44.28M -	42.83M 3.26%	42.83M 0.00%	41.30M 3.57%	40.16M 2.77%	38.99M 2.90%	38.46M 1.36%	38.21M 0.65%	37.64M 1.49%	37.58M 0.15%	37.58M 0%
weighted average shs out dil	44.28M -	42.83M 3.26%	42.83M 0.00%	41.30M 3.57%	40.16M 2.77%	38.99M 2.90%	38.46M 1.36%	38.21M 0.65%	37.64M 1.49%	37.58M 0.15%	37.58M 0%
eps	8.14 -	11.31 38.94%	12.62 11.58%	11.05 12.44%	5.26 52.40%	7.23 37.45%	6.35 12.17%	-10.49 265.20%	1.55 114.78%	0.68 56.13%	1.43 110.29%
epsdiluted	8.14 -	11.31 38.94%	12.62 11.58%	11.05 12.44%	5.26 52.40%	7.23 37.45%	6.35 12.17%	-10.49 265.20%	1.55 114.78%	0.68 56.13%	1.43 110.29%

COM:TARO

Taro Pharmaceutical Industries

Last Close

42.97

21/06 19:59

Market Cap

1.62B

Beta: -

Volume Today

147.06K

Avg: -

Preview